Relation Between Plasma Antidepressant Concentrations and Clinical Effects

  • Graham D. Burrows
  • Iain M. McIntyre
  • Kay P. Maguire
  • Bruce A. Scoggins
  • Trevor R. Norman


Studies of the plasma levels of antidepressant drugs may improve the treatment of depression and related disorders. It is approximately 20 years since plasma levels of the tricyclic antidepressant drugs first began to be measured. There are close to 100 plasma tricyclic level clinical response studies in the literature today. About one-third find a relation and two-thirds do not. The reasons for this controversy are reviewed and some directions for future research presented.


Plasma Drug Concentration Cardiovascular Side Effect Curvilinear Relation Plasma Level Monitoring Tricyclic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Burrows GD. Plasma levels of tricyclics, clinical response and drug interactions. In Burrows GD (ed): Handbook of Studies on Depression. Amsterdam: Excerpta Medica, 1977; 173–194.Google Scholar
  2. 2.
    Burrows GD, Davies B, Norman TR, et al. Should plasma level monitoring of tricyclic antidepressants be introduced in clinical practice? Commun Psychopharmacol 1978; 2: 393–408.PubMedGoogle Scholar
  3. 3.
    Risch SC, Huey LY, Janowsky DS. Plasma levels of tricyclic antidepressants and clinical efficacy: review of the literature. Part I. J Clin Psychiatry 1979; 40: 4–16.Google Scholar
  4. 4.
    Risch SC, Huey LY, Janowsky DS. Plasma levels of tricyclic antidepressants and clinical efficacy: review of the literature. Part II. J Clin Psychiatry 1976; 40: 58–69.Google Scholar
  5. 5.
    Norman TR, Burrows GD. Plasma levels of psychotropic drugs and clinical response. In Burrows GD, Werry J (eds): Advances in Human Psychopharmacology. Vol. 1. Greenwich. JAI Press, 1980; 103–140.Google Scholar
  6. 6.
    Scoggins BA, Maguire KP, Norman TR, et al. Measurement of tricyclic antidepressants. Part 2. Applications. Clin Chem 1980; 26: 805–815.PubMedGoogle Scholar
  7. 7.
    Burrows GD, Norman TR. Tricyclic antidepressants: plasma levels and clinical response. In Burrows GD, Norman TR (eds): Psychotropic Drugs, Plasma Concentration and Clinical Response. New York: Marcel Dekker, 1981; 169–204.Google Scholar
  8. 8.
    Kragh-Sorensen P, Eggert-Hansen C, Larsen N, et al. Longterm treatment of endogenous depression with nortriptyline with control of plasma levels. Psychol Med 1974; 4: 174–180.PubMedCrossRefGoogle Scholar
  9. 9.
    Kragh-Sorensen P, Hansen CE, Baastrup PC, et al. Self inhibiting action of nortriptyline antidepressive effect at high plasma levels. Psychopharmacology 1976; 45: 305–312.CrossRefGoogle Scholar
  10. 10.
    Burrows GD, Davies BM, Scoggins BA. Plasma concentration of nortriptyline and clinical response in depressive illness. Lancet 1972; 2: 619–623.PubMedCrossRefGoogle Scholar
  11. 11.
    Burrows GD, Scoggins BA, Turecek LR, et al. Plasma nortriptyline and clinical response. Clin Pharmacol Ther 1974; 16: 639–644.PubMedGoogle Scholar
  12. 12.
    Burrows GD, Maguire KP, Scoggins BA, et al. Plasma nortriptyline and clinical response-a study using changing plasma levels. Psychol Med 1977; 7: 87–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Burrows GD, Vohra J, Dumovic P, et al. Tricyclic antidepressant drugs and cardiac conduction. Prog Neuropsychopharmacol 1977; 1: 329–334.CrossRefGoogle Scholar
  14. 14.
    Gram LF, Reisby N, Ibsen I, et al. Plasma levels and antidepressive effect of imipramine. Clin Pharmacol Ther 1976; 19: 318–324.PubMedGoogle Scholar
  15. 15.
    Ballinger BR, Presley A, Reid AH, et al. The effects of hypnotics on imipramine treatment. Psychopharmacology 1974; 39: 267–274.CrossRefGoogle Scholar
  16. 16.
    Bhanji S, Lader MH. The electroencephalographic and psychological effects of imipramine in depressed inpatients. Eur J Clin Pharmacol 1977; 12: 349–354.PubMedCrossRefGoogle Scholar
  17. 17.
    Freyschuss U, Sjoqvist F, Tuck D, et al. Circulatory effects in man of nortriptyline, a tricyclic antidepressant drug. Pharmacol Clin 1978; 2: 68–71.CrossRefGoogle Scholar
  18. 18.
    Vohra JK, Burrows GD, Sloman G. Assessment of cardiovascular side effects of therapeutic doses of tricyclic antidepressant drugs. Aust NZ Med J 1975; 5: 7–11.Google Scholar
  19. 19.
    Ziegler VE, Co BT, Biggs JT Plasma nortriptyline and ECG findings. Am J Psychiatry 1977; 134: 441–443.PubMedGoogle Scholar
  20. 20.
    Ziegler VE, Co BT, Biggs JT. Electrocardiographic findings in patients undergoing amitriptyline treatment. Dis Nerv Syst 1977; 38: 697–699.PubMedGoogle Scholar
  21. 21.
    Veith RC, Friedel RO, Bloom V, et al. Electrocardiogram changes and plasma desipramine levels during treatment of depression. Clin Pharmacol Ther 1980; 27: 796–802.PubMedCrossRefGoogle Scholar
  22. 22.
    Sloman JG, Norman TR, Burrows GD. Clinical studies of antidepressant cardiotoxicity. In Burrows GD, Norman TR, Davies B (eds): Drugs in Psychiatry, Vol. 1: Antidepressants. Amsterdam: Elsevier, 1983; 173–186.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • Graham D. Burrows
  • Iain M. McIntyre
  • Kay P. Maguire
  • Bruce A. Scoggins
  • Trevor R. Norman

There are no affiliations available

Personalised recommendations